Gland Pharma reports #Q4 earnings👇
➡️Net profit at ₹192.4 cr vs ₹78.7 cr (YoY)
➡️Revenue up 95.8% at ₹1,537.5 cr vs ₹785 cr (YoY)
➡️EBITDA at ₹358.5 cr vs ₹168.4 cr (YoY)
➡️Margin at 23.3% vs 21.5% (YoY)
➡️Board recommends a final dividend of ₹20/sh
➡️Net profit at ₹192.4 cr vs ₹78.7 cr (YoY)
➡️Revenue up 95.8% at ₹1,537.5 cr vs ₹785 cr (YoY)
➡️EBITDA at ₹358.5 cr vs ₹168.4 cr (YoY)
➡️Margin at 23.3% vs 21.5% (YoY)
➡️Board recommends a final dividend of ₹20/sh